ARTICLE | Clinical News
Genta starts antisense Phase III in cancer
March 9, 2000 8:00 AM UTC
GNTA started a North American and European Phase III trial of G3139, its antisense compound, in combination with dacarbazine to treat advanced malignant melanoma. ...